Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 3,979 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert; Drug
Lead sponsor: EndoCeutics Inc.; Industry
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 63
States / cities: Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 53 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions: Placebo, Memantine Hydrochloride, OROS-Methylphenidate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Altitude Hypoxia, Ventilation, Sleep, Oxidative Stress, Neurocognitive Dysfunction
Interventions: Melatonin, Hypoxia; Dietary Supplement · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment
Interventions: EEG scan; Device
Lead sponsor: Metabolic Therapy Inc.; Other
Eligibility: 60 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions: vitamin E, donepezil hydrochloride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 15
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more

Conditions: Optic Disc Edema, Endothelial Dysfunction
Interventions: Vitamin B-Complex Supplement; Drug
Lead sponsor: National Aeronautics and Space Administration (NASA); Federal
Eligibility: 20 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mild Cognitive Impairment, Alzheimer Dementia (AD)
Interventions: Closed-loop TBS, Open-loop TBS; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 90 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Mild Cognitive Impairment, Cognitive Decline, Memory Impairment
Interventions: Aerobic exercise, Stretching/balance/range of motion exercise; Behavioral
Lead sponsor: Alzheimer's Disease Cooperative Study (ADCS); Other
Eligibility: 65 Years to 89 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 14
States / cities: Irvine, California • Palo Alto, California • New Haven, Connecticut + 10 more

Conditions: Spinocerebellar Ataxia - All Sub-types, Friedreich's Ataxia
Interventions: Ataxia rating scale; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Bipolar Disorder
Interventions: Clozapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mild Cognitive Impairment
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Duke University; Other
Eligibility: 60 Years to 82 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer, Sexual Dysfunction, Sexuality and Reproductive Issues
Interventions: radiation therapy; Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Diastolic Dysfunction
Interventions: valsartan, amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
Interventions: Left Ventricular Assist System (LVAS); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 37 more

Conditions: Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer, Chemobrain
Interventions: Transdermal nicotine, Placebo Transdermal Patch; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 23
States / cities: Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more

Conditions: Physical Activity, Cancer of the Prostate, Cognitive Impairment, Quality of Life
Interventions: Supervised Physical Activity Plus Behavioral Counseling, Supervised Physical Activity Plus Exercise Counseling; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Temporomandibular Joint Syndrome
Interventions: 3D Analysis Group, Manual Analysis Cohort; Device · Other
Lead sponsor: Dr. Dean Reeves Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Gainesville, Texas

Conditions: Cognitive Decline
Interventions: vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo; Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years to 92 Years
Enrollment: 3,424 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemodialysis
Interventions: CR845 0.5 mcg/kg, Placebo; Drug · Other
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Bridgeport, Connecticut • Hartford, Connecticut • Kansas City, Kansas + 2 more

Conditions: Heart Failure, Congestive
Interventions: OPTIMIZER System; Device
Lead sponsor: Impulse Dynamics; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Healthy, Obese
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Aging, Mild Cognitive Impairment
Interventions: Conversational Engagement; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 75 Years and older
Enrollment: 186 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Type 1 Diabetes
Interventions: glucose clamp; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.

Evidence Amyloid Scan EEG Study

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

B-Complex: A Nutraceutical SANS Countermeasure

Closed-Loop Brain Stimulation as a Potential Intervention for Cognitive Decline

Exercise in Adults With Mild Memory Problems

Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)

Clozapine for Treatment-Resistant Mania

Network-guided TMS in Early Alzheimer's Disease

Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy

Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

Prostate Cancer Survivors and Exercise and Behavioral Counseling

Temporomandibular Joint (TMJ) Positioning Accuracy and Efficiency Using a Dental Compass.

A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5

PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

Internet-based Conversational Engagement Clinical Trial

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Q.3